Industry Overview
Pharmaceuticals
Business Description
- They manufacture and distribute innovative wound care products across Europe and also have the capability to produce reagents.
- GMP manufacturing facilities in the UK and Germany.
- Operations take place in controlled environments ranging from Class D to Class A, depending on process requirements.
- They have a novel wound care product awaiting approval in April 2026, which is expected to substantially increase revenues.
Financial Summary
FY 2024 Turnover £4m
FY 2024 EBITDA £350k
Reason for Sale
Retirement
To register interest you will need to complete our Buyer Verification Process.
